Pliant Therapeutics (NASDAQ:PLRX) Hits New 12-Month Low at $12.35

Pliant Therapeutics, Inc. (NASDAQ:PLRX - Get Free Report) reached a new 52-week low on Thursday . The company traded as low as $12.35 and last traded at $12.45, with a volume of 15312 shares traded. The stock had previously closed at $12.86.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on PLRX. HC Wainwright reaffirmed a "buy" rating and issued a $48.00 price target on shares of Pliant Therapeutics in a research note on Wednesday, February 28th. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 price objective on shares of Pliant Therapeutics in a report on Wednesday, April 10th. Finally, Royal Bank of Canada boosted their price objective on Pliant Therapeutics from $50.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday, March 5th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Pliant Therapeutics has an average rating of "Buy" and a consensus target price of $49.00.

Pliant Therapeutics Trading Down 5.2 %

The company has a fifty day simple moving average of $15.23 and a two-hundred day simple moving average of $15.70. The company has a current ratio of 17.72, a quick ratio of 17.72 and a debt-to-equity ratio of 0.02. The company has a market cap of $734.33 million, a PE ratio of -4.37 and a beta of 1.12.

Institutional Investors Weigh In On Pliant Therapeutics

Several large investors have recently bought and sold shares of PLRX. Mass General Brigham Inc purchased a new position in shares of Pliant Therapeutics in the 1st quarter valued at about $4,301,000. Vanguard Group Inc. increased its holdings in shares of Pliant Therapeutics by 4.1% in the 4th quarter. Vanguard Group Inc. now owns 3,065,869 shares of the company's stock valued at $55,523,000 after acquiring an additional 120,557 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Pliant Therapeutics by 13.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,785,916 shares of the company's stock valued at $68,564,000 after acquiring an additional 434,429 shares during the last quarter. Blue Owl Capital Holdings LP purchased a new position in shares of Pliant Therapeutics in the 4th quarter valued at about $54,406,000. Finally, Exome Asset Management LLC purchased a new position in shares of Pliant Therapeutics in the 4th quarter valued at about $898,000. Hedge funds and other institutional investors own 97.30% of the company's stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.